Finally, leaving aside inhibition of CETP as a method for increasing serum HDL levels, another technique has involved studies that infused either reconstituted HDL or a version of the principal protein, ApoA-I Milano into patients with existing CHD and then assessed the “burden” of atherosclerotic disease using intravascular ultrasound (IVUS) in the coronary arteries.
In the study infusing ApoA-I Milano, the result was that after just 5 weekly infusions there was significant regression of coronary atherosclerosis.[34]
In the second study using reconstituted HDL, also given as 5 weekly infusions, the result was also a net regression of coronary atherosclerosis.[35]
J Clin Lipidol. 2011; 5(6).[34]Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290(17):2292-2300.
[35]Tardif J-C, Gregoire J, L’Allier PL, et al. Effects of Reconstituted High-Density Lipoprotein Infusions on Coronary Atherosclerosis. JAMA. 2007;297(15):1675-1682.
